Literature DB >> 9484623

Controversies regarding tamoxifen and uterine carcinoma.

P Neven1, I Vergote.   

Abstract

An increasing number of cases of endometrial cancer in women receiving tamoxifen have been reported but most are from non-randomized studies and case reports. In the last year, there have been no further results either confirming or disproving an association between tamoxifen and endometrial cancer from randomized controlled studies in breast cancer patients and those participating in chemopreventative trials with tamoxifen. Several papers have examined the possible mechanisms behind tamoxifen's endometrial effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484623     DOI: 10.1097/00001703-199802000-00003

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  3 in total

1.  The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk.

Authors:  Marian Y Williams-Brown; Sana M Salih; Xia Xu; Timothy D Veenstra; Muhammad Saeed; Shaleen K Theiler; Concepcion R Diaz-Arrastia; Salama A Salama
Journal:  J Steroid Biochem Mol Biol       Date:  2011-05-10       Impact factor: 4.292

Review 2.  Guidelines for monitoring patients taking tamoxifen treatment.

Authors:  P Neven; H Vernaeve
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.228

3.  The Role of Steroid Sulfatase as a Prognostic Factor in Patients with Endometrial Cancer.

Authors:  Won Moo Lee; Ki-Seok Jang; Jaeman Bae; A Ra Koh
Journal:  Yonsei Med J       Date:  2016-05       Impact factor: 2.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.